Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, Weber JS (2007) Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 19(10):1223–1234. https://doi.org/10.1093/intimm/dxm091

Article  CAS  PubMed  Google Scholar 

Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J et al (2023) Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med 389(6):504–513. https://doi.org/10.1056/NEJMoa2215530

Article  CAS  PubMed  Google Scholar 

ChiewWoon L, JoycelynJie Xin L, Su Pin C (2020) Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther. 20(7):687–693. https://doi.org/10.1080/14712598.2020.1749593

Article  CAS  Google Scholar 

VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO et al (2023) Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 29(9):2278–2285. https://doi.org/10.1038/s41591-023-02498-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okiyama N, Tanaka R (2022) Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int 71(2):169–178. https://doi.org/10.1016/j.alit.2022.01.001

Article  CAS  PubMed  Google Scholar 

George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S et al (2019) Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology 19(4):587–594. https://doi.org/10.1016/j.pan.2019.04.015

Article  CAS  PubMed  Google Scholar 

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–209. https://doi.org/10.1016/j.ejca.2016.02.025

Article  CAS  PubMed  Google Scholar 

George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, Price C, Farrell JJ (2019) Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology 19(4):587–594. https://doi.org/10.1016/j.pan.2019.04.015

Article  CAS  PubMed  Google Scholar 

Zhang Y, Fang Y, Wu J, Huang G, Bin J, Liao Y et al (2022) Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis. Front Pharmacol 13:817662. https://doi.org/10.3389/fphar.2022.817662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buja A, Rugge M, Damiani G, Zorzi M, De Toni C, Vecchiato A, Del Fiore P, Spina R, Baldo V, Brazzale AR, Rossi CR, Mocellin S (2022) Sex differences in cutaneous melanoma: incidence, clinicopathological profile, survival, and costs. J Womens Health (Larchmt) 31(7):1012–1019. https://doi.org/10.1089/jwh.2021.0223

Article  PubMed  Google Scholar 

Tanaka T, Sakai A, Shiomi H, Masuda A, Kobayashi T, Tanaka S et al (2021) An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab. Pancreatology 21(1):21–24. https://doi.org/10.1016/j.pan.2020.11.002

Article  CAS  PubMed  Google Scholar 

Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1):165. https://doi.org/10.1186/s40425-019-0645-6

Article  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti–programmed Death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175. https://doi.org/10.1200/JCO.2009.26.7609

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su Q, Zhang XC, Zhang CG, Hou YL, Yao YX, Cao BW (2018) Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. J Immunol Res 2018:1027323. https://doi.org/10.1155/2018/1027323

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P et al (2016) Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst. 109(4):djw260. https://doi.org/10.1093/jnci/djw260

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/JCO.2017.77.6385

Article  CAS  PubMed  Google Scholar 

Xu F, Shen Z, Tao H, Zhu Z, Tao JL, Feng ZY (2023) Immune-related pancreatitis caused by immune checkpoint inhibitor nivolumab: report of one case. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 45(2):351–354. https://doi.org/10.3881/j.issn.1000-503X.15003.

Ikeuchi K, Okuma Y, Tabata T (2016) Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report. Lung Cancer. 99:148–50. https://doi.org/10.1016/j.lungcan.2016.07.001

Article  PubMed  Google Scholar 

French JB, Sasatomi E, Gangarosa LM (2017) Ipilimumab-nivolumab combination therapy leads to biopsy proven immune-mediated pancreatitis. J Case Rep Images Med 3:46–49

Google Scholar 

Champion B, Chai SM, Bhandari M, Gunawardena D (2023) IgG4-related autoimmune pancreatitis-like mass-forming lesion on a background of immune checkpoint inhibitor immunotherapy. Pathology. 55(1):133–136. https://doi.org/10.1016/j.pathol.2022.04.010

Article  CAS  PubMed  Google Scholar 

Agrawal R, Guzman G, Karimi S, Giulianotti PC, Lora AJM, Jain S, Khan M, Boulay BR, Chen Y (2022) Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: a case report. World J Clin Cases 10(20):7124–7129. https://doi.org/10.12998/wjcc.v10.i20.7124

Article  PubMed  PubMed Central  Google Scholar 

Goyal P, Moyers JT, Elgohary BG, Hammami MB (2021) Case report: nivolumab-induced autoimmune pancreatitis. J Immunother Precis Oncol 4(4):208–211

Article  PubMed  PubMed Central  Google Scholar 

Song Z, Shih J, Seid DS (2022) Rare case of nivolumab-induced chronic pancreatitis. Clin Gastroenterol Hepatol 20(6):e1228. https://doi.org/10.1016/j.cgh.2021.10.015

Article  PubMed  Google Scholar 

Liu Y, Zhang H, Zhou L, Li W, Yang L, Li W, Li K, Liu X (2021) Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management. Front Oncol 11:627612. https://doi.org/10.3389/fonc.2021.627612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tenner S, Vege SS, Sheth SG, Sauer B, Yang A, Conwell DL, Yadlapati RH, Gardner TB (2024) American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol 119(3):419–437. https://doi.org/10.14309/ajg.0000000000002645

Article  PubMed  Google Scholar 

Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S et al (2017) International consensus for the treatment of autoimmune pancreatitis. Pancreatology 17(1):1–6. https://doi.org/10.1016/j.pan.2016.12.003

Article  CAS  PubMed  Google Scholar 

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S et al (2019) Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw 17(3):255–289. https://doi.org/10.6004/jnccn.2019.0013

Article  CAS